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LAMBERT, M. P., S. SABO, C. ZHANG, S. A. ENAM AND W. L. KLEIN. Constitutive Alzheimer's-type tau epitopes in
a neuritogenic rat CNS cell line. NEUROBIOL AGING 16(4) 583-589, 1995. -Paired helical filaments (PHFs) of Alzheimer's
disease (AD) largely comprise hyperphosphorylated forms of the cytoskeletal protein tau. AD-type tau phosphoepitopes, detected
by various monoclonal antibodies, are absent from normal adult neurons, but recent studies have shown that their expression
may contribute to neuritogenesis and axon differentiation in the developing nervous system. Therefore, we have examined a
brain nerve cell line that is spontaneously neuritogenic for possible expression of AD-type tau epitopes. The neuritogenic rat
brain cell line B103 was found to constitutively produce two AD-related epitopes of tau, detected by cellular immunofluorescence studies with the PHF-1 and Alz-50 monoclonal antibodies. Biochemical studies showed that the antibodies bound to proteins within the molecular weight range expected for phosphorylated tau isoforms. Further verification was established by use
of tau antisense oligomers, which eliminated cellular immunofluorescence due to the AD-related monoclonals and polyclonal
anti-tau but did not eliminate fluorescence due to anti-tubulin. Cells treated with tau antisense were not neurite-free. Neurites
that remained, however, were abnormal, generally short and wavy in appearance. Cellular distribution of the tau epitopes was
found to be particularly interesting. Alz-50 recognized only cytoplasmic tau whereas PHF-1 recognized nuclear tau as well as
cytoplasmic. Thus, the two epitopes are morphologically segregated within the cell. Because subcellular segregation of tau is
compromised in Alzheimer's disease, mechanisms that segregate AD-type phosphotau epitopes in Bi03 cells may have relevance
to this neurodegenerative disorder.
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PAIRED helical filaments (PHFs) are known to be the principal structures of neurofibrillary tangles, a neuronal abnormality characteristic of Alzheimer's disease (AD) (46). PHFs
comprise aberrantly phosphorylated forms of the cytoskeletal
protein tau (14,35,28). Tau normally can exist in various states
of phosphorylation, but the level of phosphorylation is considerably elevated in Alzheimer's-afflicted brain (23,26,17). Various
phosphoepitopes found in Adzheimer's-type tau can be discerned
by monoelonal antibodies, a number of which have been raised
against paired helical f'daments obtained from Alzheimer's brain
tissue. Two of these antibodies, Alz-50 (51) and PHF-1 (20,21,22),
have been found to be highly specific for degenerating neurons
in the adult human brain (119,27,13). The Alz-50 epitope is at
the amino terminal of tau. It comprises amino acids 2-10 of
tau (numbering based on the longest form of adult human tau),
a sequence that appears to be conformationally sensitive to
the hyperphosphorylation associated with AD tan (32,16). The
PHF-1 epitope is carboxy to the microtubule binding domains
and depends on phosphorylation of ser396 in AD tau (4). Alz-
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50 and PHF-1 epitopes also are found transiently in the developing brain where their expression has been attributed to the
massive nerve cell death that occurs during embryogenesis and
brain development (reviewed in 5). These epitopes also can be
induced in mature neurons that are degenerating due to experimental manipulations (41,8).
The AD-type tau epitopes, however, are not always associated with cell death. Recent studies of the PHF-I phosphotau
epitope in developing chick brain neurons, for example, have
shown it is expressed transiently by viable cells undergoing neuritogenesis and axon differentiation. The PHF-I Alzheimer'stype posttranslational modification of tau thus is highly conserved
in evolution (43), complementing the highly conserved nature
of tau itself (34), and is linked to neuritogenesis in immature
neurons.
Because AD-type tau phosphoepitopes can occur in viable
immature neurons, they also are likely to occur in cloned nerve
cell lines, which typically express multiple features of immature
neurons. Such cell lines provide homogeneous experimental systems, and they would be of use for investigations of the regulatory
cell biology of Alzheimer's type tau phosphorylation. The current
work has used the PH F- I and Alz-50 antibodies to investigate
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tau epitopes expressed by the B103 rat nerve cell line. This line
is of particular interest because it is spontaneously neuritogenic
and is derived from the central rather than the peripheral nervous system (47). Results here show that the B103 rat ceils constitutively produce both the Alz-50 and PHF-I tau epitopes. The
Alz-50 epitope is exclusively extranuclear, but the PHF-1 epitope
is abundant in the nuclear as well as extranuclear compartments.
METHOD

Cell Culture
The B103 rat CNS cell line was a generous gift of D. Schubert
of the Salk Institute, CA. Cultures are maintained in Dulbecco's
Modified Eagle medium, antibiotics (streptomycin, penicillin,
and fungizone, Gibco/BRL), and 10o7o fetal calf serum (Gibco/
BRL). For experiments, cells are plated on poly L-lysine-coated
glass coverslips or Permanox LabTek plates (8 wells/plate,
Nunc) at a density of 9 x 105 cells/cm 2 in a total volume of
0.4 ml Cells are allowed to grow for 24 h before fixing.

Immunocyt ochemistry
Cells are fixed with 3.7o70 formaldehyde for 15 min at 37°C
and permeabilized with 0.1°70 Triton X-100 for 5 min at room
temperature. After washing with PBS containing l°T0 bovine
serum albumin and 1% DMSO (PBS+), the cells are blocked
with 10070normal goat serum in PBS+ for 15 min. After another
wash with PBS+, primary antibodies (PHF-1, Alz-50, and others) are added and allowed to react for 1.5 h at 37°C. After
washing for 3 x 5 min with PBS+, FITC-conjugated anti-mouse
IgG is added and allowed to react for 1.5 h in the dark. A final
3 x 5 min wash with PBS+ and then one with PBS are done
before mounting. Images are taken using a Hamamatsu 10-bit
digital CCD camera with the MetaMorph imaging system (Universal Imaging, Westchester, PA) on a Nikon Diaphot microscope equipped with epifluorescence capability. The MetaMorph
system is also used to analyze the images for fluorescence intensity. PHF-1 (2.7 mg/ml) and Alz-50 (300/~g/ml) monoclonal
antibodies were generous gifts of Jonathan Chong of Abbott
Laboratories. They were used at 1:200 and 1:100 dilution, respectively, for immunocytochemistry and 1:4000 for immunoblots. Polyclonal anti-tau (against embryonic chick brain) was
obtained from Sigma Chemical and used at 1:200 for immunocytochemistry and 1:4000 for immunoblots. This antibody does
not cross-react with MAPI, MAP2, and tubulin, according to
the company literature, and shows wide cross-reactivity amongst
mammalian species (43,44). Polyclonal anti-tubulin (against
embryonic chick brain) was obtained from ICN Biomedical, and
used at 1:200. Tau-1 antibody was obtained from Boehringer
Mannheim and used at 1:1000.

Radioimmunoprecipitation Assay
Cultures are grown as described for 24 h in a 60 mm dish.
After rinsing with Hanks basic salt solution (37C, Gibco/BRL)
and met/cys free DMEM (ICN, supplemented with 0.584 mg/ml
glutamine) at 37 °C, cells are incubated in the met/cys free DMEM
for 20 min. 150 mCi of 35S-methionine/cysteine (NEN, Express) is added and the culture is grown overnight at 37C. After
removal of the medium and two washes with chilled PBS, cells
are harvested in 10 mM Tris-HCl, pH 7.4 containing 0.8 M
NaC1, 3 mM EGTA, and 1 mM PMSF (fresh). After brief
homogenization, the cell lysate is centrifuged at 30,000 × g
for 20 min at 4°C. The supernatant cell lysate can be frozen at
this point. 100 izl of lysate is used for each precipitation. 5/~1
of PHF-I antibody (4.6 mg/ml) is added to the lystate and in-

cubated for 1.5 h on ice. Meanwhile, a solution of protein A
Sepharose is prepared in PBS containing 0.1°70 SDS, 1°70Triton
X-100, fresh deoxycholate, PMSF and aprotinin (PBS-TDS).
200/d of protein A Sepharose is added to each sample and the
sample is shaken at 1600 rpm for 1.5 h at 4°C. The Sepharose
is then washed 3 x with PBS-TDS. 25 #1 of Laemmli buffer (30)
is added to each sample and the sample is boiled for 5 min.
Samples are then centrifuged and run on 8°7o SDS-PAGE gels
(Novex). The gel is fixed in 10°70 acetic acid and 2507o isopropanol for 30 min and soaked in Amplify (Amersham) for 30 min
before being dried and exposed to X-ray film.

AIz-50 Immunoprecipitation
Cells are grown in poly L-lysine-coated 60 mm dishes for
24 h and harvested with cold PBS and 0.02°70 EDTA. Then cells
are briefly centrifuged and lysed with lysis buffer (150 mM
NaC1; 50 mM Tris-HCl, pH 7.5; 1°70Triton x 100; 0.1070 SDS;
2 mM EDTA; added cocktail of protease inhibitors before use:
2 mM PMSF, 0.2 TIU/ml aprotinin, 1 mg/ml leupeptin and
50 mM NaF, 1070 deoxycholate acid, 30 mM NaH2PO4). After
centrifugation at 14,000 × g for 10 min, the supernatant is
assayed for protein content, and then stored in 100/zg aliquots.
For immunoprecipitation, 2 t~l of Alz-50 antibody is added and
allowed to incubate for 2 h on ice. Then, 200 Itl of protein A
Sepharose prewashed with lysis buffer is added to each tube
and the tube is shaken in the cold for 1.5 h. Unbound proteins
are removed by 4 washes with lysis buffer. Bound proteins are
solubilized in 20/zl Laemmli buffer (30), boiled for 5 min, separated by electrophoresis on a 14°70SDS-PAGE gel (Novex), and
then transferred to nitrocellulose using a Hoeffer transfer apparatus. The nitrocellulose is then blocked for 2 h in PBS+ 0.1 070
Tween 20 and 3°70nonfat milk incubated with Alz-50 antibody
(1:100 in PBS + 0.1070 Tween 20) for 1 h, washed 3 x 15 min with
PBS+ 0.1 070Tween 20, and incubated with mouse IgG secondary antibody (Vector Laboratories, Inc) for 30 min. After washing, bound proteins are treated with ABC reagent for 30 min and
visualized with DAB.
ECL immunoblot and immunoprecipitation. Cells were
grown in 60 mm dishes in DMEM, 10070FCS, for 24 h, and harvested in 0.01 M Tris, pH 7.4, supplemented with 1 mM EDTA,
1 mM EGTA, 0.15 M NaC1, 1°70Triton X-100, and a cocktail
of protease inhibitors made up fresh (2 mM PMSF, 0.2 TIU/ml
aprotinin, 1 mg/ml leupeptin, 50 mM NaF, and 1 mg/ml pepstatin A). Cells were lysed by homogenization and the protein
content was determined. For an immunoblot, 20 #g of protein
was added to an equal volume of Laemmli buffer and boiled for
5 min. This sample was then loaded on an 8°70 polyacrylamide
gel (Novex) and electrophoresed under denaturing conditions.
The separated proteins were then transferred to a nitrocellulose
membrane in the cold using a Hoeffer transfer apparatus. The
membrane was then washed, blocked with 10°70nonfat dry milk
and probed with primary antibody for 1.5 h. After extensive
washing, the antibody was conjugated to HRP-labeled secondary for 1 h and visualized with ECL reagents. For an immunoprecipitation, 250 izg of protein was first precleared with Protein A Sepharose which has been washed with PBS containing
1°70Triton-X-100, 0.1070 SDS, 1°70BSA, and 5 mg/ml fresh deoxycholate for 30 min. Primary antibody (13/~g) was then added
and the solution allowed to sit on ice for 1 h with occasional
shaking. Protein A Sepharose was then added and the solution
was shaken at 1600 rpm overnight at 4°C. The Sepharose was
precipitated by centrifugation and then washed three times with
the above collection buffer to remove unbound proteins. Bound
proteins were then solubilized in 25 of Laemmli buffer by boil-
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ing for 5 min. The solution was briefly centrifuged and the entire
supernate was loaded on an 8% Novex gel and electrophoresed
as described above. Visualization of the separated, transferred
proteins was also as described above, using the ECL protocol.
A n tisense A d d i t i o n

Cultures are plated at 2 × 105 cells/ml in a total volume
of 0.2 ml/well in DMEM supplemented with the N2 mixture of
Bottenstein and Sato (2). A :25 base deoxyoligonucleotide corresponding to the inverse complement of the sequence from - 1 4
to + 11 of rat tau (generously provided by Abbott Laboratories)
is added to the medium at 50/~M concentration 10 rain after
plating and at 20-h intervals thereafter. At 60 h, cultures are
fixed and permeabilized for 5 min with 0.2% Triton X-100. They
are double-labeled for PHF-I and tubulin or PHF-1 and tau
as described above. The secondary antibodies used are FITCconjugated anti-rabbit IgG and Texas Red-conjugated antimouse IgG.
RESULTS

The B103 rat neuroblastoma cell line, derived from a rat CNS
tumor, has various enzymatic characteristics of neuronal cells

B

D
FIG. 1. PHF-1 and Alz-50immunoreactivityare present in newlyplated
B103 cells. (A,B) Phase and fluorescent micrographs, respectively, of
PHF-1 immunoreactivity in B 103 cells; (C,D) Phase and fluorescent
micrographs, respectively, of Alz-50 immunoreactivity in similar cells.
Arrow indicates long process with more intense PHF-1 immunoreactivity. Bar in (D) equals 25 microns. B103 cells were cultured and immunostained for PHF-1 and Alz-50tau as describedin the Method section.

and spontaneously produces neurites in culture (47). Because
axon formation and differentiation correlate with PHF-I tau
expression in the developing CNS, we asked if the B103 cell
line might also express AD-related tau epitopes. B103 cells
were grown for 24 h, fixed, and probed for these epitopes with
PHF-1 or Alz-50 monoclonal antibodies. Visualization was with
FITC-conjugated anti-mouse IgG. As shown in Fig. 1, both
PHF-1 and Alz-50 antigens were expressed strongly in every cell
observed, both in the cell bodies and neuritic processes. Neuritic expression of PHF-1 tau was uniform out to the growth
cone area, although as cell polarity developed, PHF-1 tau appeared more abundant in the thin, axon-like neurite (Fig. IB,
arrow). Alz-50 staining was stronger in proximal areas of the
neurite, in many instances tapering off near the growth cone,
with no evidence of polarity.
Of particular interest, the location of these tau antigens
differed within the soma. The PHF-1 epitope was found in
both the nucleus and cytoplasm, while the Alz-50 epitope was
excluded from the nucleus. Antigens to polyclonal tau antibody
were found in all cellular compartments (11, see also the tau
sense control in Fig. 4F). Nuclear PHF-1 immunoreactivity was
relatively more abundant than cytoplasmic, although the difference in intensity may be due partially to the relative thickness of the nucleus. In addition, several days after plating, two
populations of cells could be observed, those which had both
nuclear and cytoplasmic PHF-I labeling and those which had
only cytoplasmic labeling (data not shown). The decrease in
nuclear PHF-1 immunoreactivity did not correlate with any
apparent morphological property. Alz-50 immunofluorescence
did not show any changes with respect to location or intensity
during this time.
The Alz-50 antibody recognizes an epitope that depends on
the 2-10 amino acid residues of tau (16). To verify that Alz-50
immunostaining found in B103 cells is also due to tau, proteins
from B103 cell lysate were immunoprecipitated with Alz-50 antibody. This immunoprecipitate was then solubilized, separated
by electrophoresis and reprobed with Alz-50 antibody. The result is shown in Fig. 2. Three proteins in cell lysate reacted with
the Alz-50 antibody. Their apparent molecular weights are approximately 51, 53, and 60 kDa. The two lower bands are in the
range of fetal tau (29,15); the upper band is that of the lowest
molecular weight form of PHF-tau (28,17,35).
Because the calcium ionophore A23187 has been shown to affect the expression of Alz-50 in hippocampal cells (41), the effect
of this agent on BI03 cells was also assessed. A concentrationdependent morphological effect was seen after 90 rain of incubation, with 5 ~M ionophore causing a retraction of neurites
while 0.5 ~M had no effect (11, data not shown). Cell bodies
changed from a rounded shape to one more triangular or fusiform and the neurites assumed a dystrophic or wavy appearance.
In the presence of 50 #M ionophore, most of the cells detached
from the substratum. The remaining attached cells had almost
completely retracted neurites. Despite significant morphological changes, Alz-50 immunofluorescence was unchanged.
PHF-tau proteins, including those recognized by the PHF-1
antibody, have molecular weights in the 60-68 kDa range (28,
17,35). The PHF-1 antibody also recognizes an epitope in fetal
tau, the smallest form of tau with a molecular weight of 5558 kDa (4,8) and epitopes in cultured peripheral neuroblastoma
cells from 50-58 kDa (44,36,40,11). Attempts to analyze the
Mr of the PHF-1 antigen in B103 cell lysate by western blot
showed no specific bands. Therefore, a more sensitive radioimmunoprecipitation analysis was performed. BI03 cells were
grown overnight in cys/met free medium with 35S-methionine.
Protein was precipitated from cell lysate using the PHF-1 anti-
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FIG. 2. Alz-50immunoblot of B103 cell lysate shows three bands in the
molecular weight range of 50 to 60 kDa. Left: molecular weight standards. Lane A: Alz-50 antibody, Lane B: No primary. Arrows indicate
the bands precipitated by the Alz-50 antibody at approximately 51,53,
and 60 kDa, respectively.

body and adsorption to Protein A Sepharose. The major specific
protein which was immunoprecipitated by the PHF-1 antibody
had a molecular weight of 60 kDa and was not present when
the primary antibody was omitted from the procedure (Fig. 3).
Although multiple forms of the tau protein were not observed,
the molecular weight was in the range for adult phosphorylated
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FIG. 3. RIPA analysis shows a 60 kDa band with the PHF-1 antibody
in B103 cellsgrown for 24 h. Left: molecularweight standards. Lane A:
PHF-1 antibody, Lane B: buffer alone. Arrow indicatesthe major 60 kDa
band precipitated with PHF-I antibody.

tau. Because the band found with radioimmunoprecipitation
was faint and immunoblots were unsuccessful, additional studies were done to verify the nature of PHF-1 immunoreactivity
by eliminating all tau proteins from the cells by transiently introducing antisense tau DNA. Previous work showed that tau
antisense deoxyoligonucleotides administered from the time of
plating eliminated tau expression in cultured cerebellar macroneurons and caused them to maintain an array of minor neurites
without forming morphologically distinct axons and dendrites
(7,6). In these same cells, exposure to tau antisense after establishment of an axon-like neurite caused the retraction of this
neurite. To determine if tau antisense deoxyoligonucleotides
caused any changes in BI03 cultures, cells were given a 25 base
deoxyoligonucleotide corresponding to the inverse complement
of the sequence from -14 to + 11 of rat tau. After 60 h, cultures
were fixed and processed for immunofluorescence using various antibodies. Cells administered tau antisense deoxyoligonucleotides had only minor neurites (Fig. 4A), most of which
appeared wavy or abnormally shaped, whereas cells administered tau sense deoxyoligonucleotides had essentially normal
neurites (Fig. 4 B,D,F,H) compared to no addition controls.
Compared to cells given tau sense deoxyoligonucleotides, the
cells given tau antisense had dramatically decreased PHF- 1 and
polyclonal tau staining (Fig. 4 C,D,E,F). Nuclear as well as cytoplasmic staining was eliminated. In contrast, tau antisense had
no effect on immunolabeling for the cytoskeletal protein tubulin, illustrating selectivity of the response (Fig. 4 G,H). Note
that the apparent nuclear staining for tubulin in occasional cells
was due to label associated with a spindle apparatus; although
the BI03 cells spontaneously make neurites, they are not postmitotic. Absence of PHF-I and tau immunoftuorescence but
retention of tubulin staining strongly suggest that the immunofluorescence seen with the PHF-1 antibody is due to tau protein.
This conclusion is verifed by the nuclear immunoprecipitation
experiment presented next.
The nuclear concentration of PHF-1 tan immunostaining
and its lack of reaction in western blots led us to the speculation that PHF-1 antibody was reacting with nuclear tau. Accordingly, a nuclear fraction prepared by the procedure of Loomis
et al. (38), was probed with antibody against polyclonal tau;
additionally, PHF-l-reactive protein was immunoprecipitated
from the nuclear fraction and probed with polyclonal tau antibody. The polyclonal tau antibody used for these experiments
previously has been characterized by Pope et al. (44) and shown
to specifically recognize tau isoforms cross-reactive with PHF-1
and Tau-l. As shown in Fig. 5, the polyclonal tau antibody recognized tau in the B103 nuclear extract (Lane 2), with the highest of three molecular weight forms present in greatest amount.
Most important, the proteins that were immunoprecipitated
from the nucleus by the PHF-1 tau antibody also were recognized by the polyclonal tau antibody (Lane 3). Again, the most
prominent form was the highest molecular weight band at approximately 60 kDa. The total number of forms recognized
cannot yet be determined because the regularity of the bands
indicate some degradation may have taken place. As expected,
proteins from the whole cell lysate (Lane 1) also were recognized
by polyclonal tau antibody. In a separate gel, both the nuclear
extract and the total lysate also gave a positive signal with Tau- I
antibody (data not shown). Results were similar to polyclonal
anti-tau in the nuclear extract, with the higher of two molecular weight forms more prominent. The immunoprecipitationand
immunoblot data thus verify that BI03 cells express in their
nucleus a PHF-l-reactive form of tau protein.
Several other cell lines also were examined for PHFl-tau immunofluorescence (11, data not shown). The F3 variant of PCI2
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FIG. 4. Exposure to antisense:Eauin the medium causes loss of neurites
and loss of immunolabeling after 60 h. B103 cells were plated on poly
L-lysine and exposed to sense or antisense tau DNA (50 #M) for 60 h
before fixing and observation with the Diaphot. (A,B) Phase micrographs: antisense and sense tatn, respectively; (C,D) PHF-I tau immunofluorescence: antisense and sense tau, respectively•(E,F) Polyclonal
tau immunofluorescence: anti,;ense and sense tau, respectively. (G,H)
Tubulin immunofluorescence:antisenseand sensetau, respectively.Note
the absence of PHF-1 tau and polyclonal tau immunoreactivity with
antisense tau DNA (C,E). Bar in (C) equals 50 microns.

cells had very weak Alz-50 and PHF-1 labeling. The mouse
neuroblastoma line N 1E-115 had a heterogenous expression of
Alz-50 tau, with some cell,; having high levels of antigen and
others having relatively lower levels. The human neuroblastoma
HCN-IA cells, differentiated or un-differentiated, did not express Alz-50 or PHF-1 tau protein. The SH-SY5Y human neuroblastoma cell line spontaneously expressed the PHF-1 epitope
(40), while NTera 2 cells expressed PHF-1 tau only after differentiation with retinoic acid (45). These findings demonstrate that
expression of the PHF-1 and Alz-50 epitopes varies widely in
different cell lines of neural origin.
DISCUSSION
Data presented here have shown that the PHF-1 and Alz-50
epitopes of tau are present constitutively in B103 rat neuroblastoma cells. The B103 cell line is of particular interest because
of its CNS origin and its ability to spontaneously produce neu-

FIG. 5. Nuclear proteins immunoprecipitated with PHF-I are recognized by polyclonal tau antibody. Lane 1:BI03 whole cell lysate was
immunoblottedwith polyclonalanti-tau. Lane 2: Proteins from a nuclear
fraction of B103 cells prepared according to Loomis et al. (38) were
immunoblotted with polyclonal anti-tau. Lane 3: Another aliquot of
this fraction was immunoprecipitated with PHF-1 antibody and then
reprobed with polyclonalanti-tau. Molecularweight markers are shown
on the right. The results indicate cross reactivityis seen betweennuclear
tau and PHF-1 antibody.

rites. Several other lines that were examined also expressed the
PHF-1 epitope. Only B103 cells, however, showed robust levels
of Alz-50 immunoreactivity. The Alz-50 epitope was exclusively
cytoplasmic; the PHF-I immunoreactivity occurred throughout
the cytoplasm but also was found in the nucleus, where it showed
cross-reactivity with nuclear tau. The data confirm that these
Alzheimer's-type tau epitopes are not simply the products of
dying cells. Of particular interest, their subcellular distribution patterns indicate differences in trafficking and, presumably,
function.
AD-type tau epitopes have been seen previously in cell culture
systems. Alz-50 immunoreactivity has been reported in association with various neurodegeneration paradigms (41). Recently,
in rat hippocampal cells, Alz-50 immunoreactivity was found
to increase during the degenerative cascade evoked by 13/A4 peptides (49). A similar association with B/A4-evoked degeneration
has been seen in postmitotic SH-SY5Y human neuroblastoma
cells (31). Prior to degeneration, these various cell culture systems expressed the Alz-50 epitope at low levels in contrast to
B103 cells. The robust expression of Alz-50 tau in the B103 line
shows that it is not exclusively the product of dying cells. Similar to the association of the Alz-50 epitope with viable B103 cells,
the expression of the PHF-1 epitope also is not dependent on
neurodegeneration. In the developing CNS, PHF-1 tau localizes
to immature axons of viable neurons developing in vivo and in
culture (43). A recent report also has shown that the PHF-1 epitope is spontaneously present in the LAN human neuroblastoma
cell line, where it is downregulated by heat shock (8).
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Phosphorylation, including the sort seen in Alzheimer'safflicted neurons (42,39), decreases the ability of tau to stabilize microtubules, thereby increasing cytoskeletal plasticity. This
phenomenon applies to the PHF-1 epitope (4) as well as other
sites of tau phosphorylation (1,18,27). Excessive destabilization
may give rise to the dystrophic neurites found in A D brain tissue. Physiologically, phosphorylation-evoked cytoskeletal plasticity is associated with mitosis (48) as well as neuritogenesis.
Available data suggest the kinase cascades of either mitosis or
neuritogenesis could lead to elevated levels of tau phosphorylation. In proliferating SH-SY5Y human neuroblastoma cells,
P H F - I immunoreactivity varies as a function of the cell cycle,
with upregulation observed at mitosis (44). In differentiated
SH-SY5Y cells, stimulation of integrins, a known neuritogenic
receptor, causes a marked increase in PHF-1 immunofluorescence (40). In vitro experiments have shown that kinases coupled to the cell cycle will phosphorylate tau, with cdc2 kinase
and mitogen activated protein (MAP) kinase producing AD-type
epitopes, including the PHF-1 epitope (33,10,9). Interestingly,
cdc2 kinase, M A P kinase, and PHF-1 immunoreactivity all
downregulate in vivo following neuronal differentiation (3,43,
24). Similar decreases in cdc2 kinase and PHF-1 immunoreactivities have been observed in association with retinoic acidinduced differentiation in neuroblastoma cell lines (12,40). In
AD-brain, upregulation of cdc2 kinase (33) is consistent with
the idea that postmitotic brain cells in A D may be responding
aberrantly to a mitogenic signal. Ectopic mitogenic signals have
been hypothesized to evoke apoptosis in postmitotic cells, such
as neurons (25), and apoptosis has been linked to Alzheimer's
pathogenesis in cell culture studies (37)

It is not understood why tau is in the nucleus, nor why it contains the PHF-1 but not the Alz-50 epitope. Loss of immunofluorescence by antisense tau oligonucleotides eliminates the
possibility that the immunoreactivity is an artifact. Nuclear tau
previously has been reported to occur in proliferating primary
cell cultures and in two cell lines (38,50). This tau was correlated
with expression of a 2 kDa m R N A , the untranslated region o1
which was hypothesized to target the protein to regions and
functions not associated with microtubules. The current results
extend these previous observations by showing that nuclear tau
is present in other human neural cell lines and is phosphorylated
to generate an AD-type epitope.
Nuclear tau and its phosphorylation may have a bearing on
tau anomalies seen in Alzheimer's disease. Normally in mature
neurons, tau is an axonal protein, but in AD, hyperphosphorylated tau accumulates ectopically in the somatodendritic compartment. Hypothetically, ectopic somatic tau in A D could
derive from disruptions in pathways that transport tau to the
nucleus and cause its nuclear phosphorylation. The nature of
such disruptions is unknown, but recent studies of B/A4-evoked
neurodegeneration have shown that neuronal apoptosis, which
leads to breakdown of nuclear structure, could be involved (37).
The BI03 rat brain cell line should prove to be a useful model
for future studies of the regulatory cell biology of tau transport
and phosphorylation and their relationship to mechanisms of
Alzheimer's pathogenesis.
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